{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:28:09Z","timestamp":1792621689802,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ad.2025.104562","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T02:19:24Z","timestamp":1765592364000},"page":"104562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Experience With Secukinumab for Hidradenitis Suppurativa: A Multicenter Retrospective Analysis of 263 Patients From the SECU-SPAIN Study"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1378-1590","authenticated-orcid":false,"given":"A.","family":"Martorell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Vilarrasa-Rull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Fernandez-Crehuet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Molina-Leyva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mansila-Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Garcia-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Garbayo-Salmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Ortiz-Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Alfageme-Roldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Garcias-Ladaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bassas-Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Fuertes-de-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Carnero-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Almenara-Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Torres-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Aguayo-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gil Pallares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fornons-Servent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Gracia-Darder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Mora-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pericet-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Haselgruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ochando-Ibernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Men\u00e9ndez-Parron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Masferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gamissans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Solera-Talamante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Imbernon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Melgosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2025.104562_bib0190","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ad.2025.104562_bib0195","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","article-title":"Hidradenitis suppurativa: a comprehensive review","volume":"60","author":"Alikhan","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104562_bib0200","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ad.2015.06.004","article-title":"An update on hidradenitis suppurativa (part I): epidemiology clinical aspects, and definition of disease severity","volume":"106","author":"Martorell","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.104562_bib0205","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/jid.2012.255","article-title":"Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota","volume":"133","author":"Vazquez","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2025.104562_bib0210","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jaad.2012.07.027","article-title":"Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States","volume":"68","author":"Cosmatos","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104562_bib0215","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/CCID.S111019","article-title":"Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment","volume":"10","author":"Napolitano","year":"2017","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.ad.2025.104562_bib0220","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/1744666X.2018.1449647","article-title":"An update on the pathogenesis of hidradenitis suppurativa: implications for therapy","volume":"14","author":"Negus","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.ad.2025.104562_bib0225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ad.2025.104562_bib0230","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104562_bib0235","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4103\/ijdvl.IJDVL_69_18","article-title":"Hidradenitis suppurativa: a systematic review and meta-analysis of therapeutic interventions","volume":"85","author":"Tchero","year":"2019","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.ad.2025.104562_bib0240","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2025.104562_bib0245","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s40265-021-01566-2","article-title":"Clinical implementation of biologics and small molecules in the treatment of hidradenitis suppurativa","volume":"81","author":"Aarts","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ad.2025.104562_bib0250","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/12034754211035667","article-title":"Treatment outcomes of IL-17 inhibitors in hidradenitis suppurativa: a systematic review","volume":"26","author":"Kashetsky","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ad.2025.104562_bib0255","series-title":"Novartis Receives European Approval for Cosentyx\u00ae as First and Only IL-17a Inhibitor for Hidradenitis Suppurativa","year":"2023"},{"key":"10.1016\/j.ad.2025.104562_bib0260","series-title":"FDA Approves Novartis Cosentyx\u00ae as the First New Biologic Treatment Option for Hidradenitis Suppurativa Patients in Nearly a Decade","year":"2023"},{"key":"10.1016\/j.ad.2025.104562_bib0265","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2025.104562_bib0270","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/bjd\/ljae098","article-title":"Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials","volume":"190","author":"Zouboulis","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.104562_bib0275","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.1111\/jdv.19681","article-title":"International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: a post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab","volume":"38","author":"Zouboulis","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104562_bib0280","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.17822","article-title":"Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa","volume":"181","author":"Prussick","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.104562_bib0285","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ad.2019.07.007","article-title":"Moderate to severe hidradenitis suppurativa successfully treated with secukinumab","volume":"111","author":"Villegas-Romero","year":"2020","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"10.1016\/j.ad.2025.104562_bib0290","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","article-title":"Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial","volume":"82","author":"Casseres","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104562_bib0295","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1111\/jdv.16605","article-title":"Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases)","volume":"34","author":"Reguia\u00ef","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104562_bib0300","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1111\/jdv.17178","article-title":"Effectiveness of secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting","volume":"35","author":"Ribero","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104562_bib0305","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1111\/jdv.18685","article-title":"Long-term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: a retrospective single-centre case series (23 patients)","volume":"37","author":"Melgosa Ramos","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104562_bib0310","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s13555-023-00906-2","article-title":"Short-term effectiveness safety, and potential predictors of response of secukinumab in patients with severe hidradenitis suppurativa refractory to biologic therapy: a multicenter observational retrospective study","volume":"13","author":"Fernandez-Crehuet","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2025.104562_bib0315","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/CCID.S449367","article-title":"Secukinumab in hidradenitis suppurativa patients who failed adalimumab: a 52-week real-life study","volume":"17","author":"Martora","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.ad.2025.104562_bib0320","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s13555-024-01209-w","article-title":"Insights into the window of opportunity and outcome measures in patients with moderate to severe hidradenitis suppurativa treated with secukinumab: a real-world study","volume":"14","author":"Haselgruber","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ad.2025.104562_bib0325","series-title":"Dermatologic Surgery","first-page":"623","article-title":"Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus: surgical approach","author":"Hurley","year":"1996"},{"key":"10.1016\/j.ad.2025.104562_bib0330","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.104562_bib0335","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/jdv.16183","article-title":"Defining hidradenitis suppurativa phenotypes based on the elementary lesion pattern: results of a prospective study","volume":"34","author":"Martorell","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104562_bib0340","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/jdv.18632","article-title":"Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa","volume":"37","author":"Tzellos","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104562_bib0345","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104562_bib0350","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104562_bib0355","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/jdv.20472","article-title":"European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: Treatment","volume":"39","author":"Zouboulis","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.104562_bib0360","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","article-title":"The levels of evidence and their role in evidence-based medicine","volume":"128","author":"Burns","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.ad.2025.104562_bib0365","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/cpt.946","article-title":"Harnessing the power of real-world evidence (RWE): a checklist to ensure regulatory-grade data quality","volume":"103","author":"Miksad","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ad.2025.104562_bib0370","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence \u2013 what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025008385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025008385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:58:20Z","timestamp":1776844700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731025008385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0001731025008385"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2025.104562","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Experience With Secukinumab for Hidradenitis Suppurativa: A Multicenter Retrospective Analysis of 263 Patients From the SECU-SPAIN Study","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2025.104562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"104562"}}